Literature DB >> 19170712

What should be done in an operating room when an insulinoma cannot be found?

Nassir Rostambeigi1, Geoffrey B Thompson.   

Abstract

Insulinoma is the most common (functioning) islet cell tumour of the pancreas and is highly curable with accurate localization and precise extirpation of the often benign, solitary lesion. Although previous reports describe high success rates without pre-operative localization, more recent recognition of the overlap among causes of endogenous hyperinsulinism, coupled with the deleterious long-term effects of blind distal pancreatectomy and re-operation, mandate the need for precise pre-operative localization or regionalization of the tumour(s). If these criteria have not been met and the surgeon finds him/herself in the operating room without a localized or regionalized tumour, the operation should be concluded without resection, the diagnosis reconfirmed, and a calcium stimulation test performed. At experienced centres, this can be often carried out within 24-48 h and the patient returned to the operating room for a gradient-guided resection. Intraoperative venous sampling for insulin might be an option in the future but its accuracy has not been validated in sufficient numbers of patients to date.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170712     DOI: 10.1111/j.1365-2265.2009.03527.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

1.  Selective Arterial Calcium Stimulation With Hepatic Venous Sampling Differentiates Insulinoma From Nesidioblastosis.

Authors:  Scott M Thompson; Adrian Vella; Geoffrey B Thompson; Kandelaria M Rumilla; F John Service; Clive S Grant; James C Andrews
Journal:  J Clin Endocrinol Metab       Date:  2015-08-27       Impact factor: 5.958

Review 2.  Diagnosis and management of insulinoma.

Authors:  Takehiro Okabayashi; Yasuo Shima; Tatsuaki Sumiyoshi; Akihito Kozuki; Satoshi Ito; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

3.  Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.

Authors:  Yaping Luo; Qingqing Pan; Shaobo Yao; Miao Yu; Wenming Wu; Huadan Xue; Dale O Kiesewetter; Zhaohui Zhu; Fang Li; Yupei Zhao; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

Review 4.  Pancreatic insulinomas: Laparoscopic management.

Authors:  Pantelis T Antonakis; Hutan Ashrafian; Alberto Martinez-Isla
Journal:  World J Gastrointest Endosc       Date:  2015-11-10

5.  Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.

Authors:  Meike Körner; Emanuel Christ; Damian Wild; Jean Claude Reubi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-06       Impact factor: 5.555

6.  Insulinoma and anaesthetic implications.

Authors:  Jyotsna Goswami; Pallavi Somkuwar; Yogesh Naik
Journal:  Indian J Anaesth       Date:  2012-03

7.  Endogenous hyperinsulinism: diagnostic and therapeutic difficulties.

Authors:  Esma Leila Gouta; Hichem Jerraya; Wejih Dougaz; Mohamed Ali Chaouech; Ibtissem Bouasker; Ramzi Nouira; Chadly Dziri
Journal:  Pan Afr Med J       Date:  2019-05-27

8.  A comparison of three (67/68)Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator.

Authors:  Andreas Jodal; Brigitte Lankat-Buttgereit; Maarten Brom; Roger Schibli; Martin Béhé
Journal:  EJNMMI Res       Date:  2014-06-22       Impact factor: 3.138

Review 9.  Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.

Authors:  Irina Velikyan; Olof Eriksson
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.